Sensitivity and Specificity of Gold Chromatography Immunoassays IgM/IgG Antibody Test for COVID-19: Review of the Current Literature
DOI:
https://doi.org/10.52981/sjms.v15i2.1523Keywords:
COVID-19, Rapid Test, IgM/IgG, sensitivity, specificity, limited-resourceAbstract
Background: The World Health Organization recommends molecular tests Polymerase Chain Reaction (PCR) to the diagnosis of coronavirus disease of 2019 (COVID-19), which detect the Severe Acute Respiratory Syndrome (SARS-Coronavirus 2) virus RNA. However, these tests are expensive and give a high negative result. There were urgent medical and public health needs for early diagnosis and treatment to minimize the spread of COVID-19. This review aimed to summarize known to date information about the latest research progress of the sensitivity and specificity of rapid combined IgM/IgG antibody test to diagnose the pandemic novel coronavirus disease of 2019 (COVID-19).
Methods: Databases such as PubMed, Google Scholar, Science Direct, Web of Science electronic databases were search related articles published between January 23, 2020 and April 29, 2020, using the following search terms: “COVID19 or COVID-19,” “novel coronavirus,” “SARS CoV-2 or SARS CoV2,” “Rapid antibody test,” “IgM/IgG,” “sensitivity,” “specificity.”
Results: The review included eight clinical studies for a total of 782 patients with COVID-19 and 631 healthy controls. The sensitivity and specificity of gold chromatography immuno-assays (GCIAs) IgM/IgG rapid test vary greatly among published studies. Of the eight shortlisted studies, the IgM/IgG sensitivity ranged from 73.9% to 89.3% in six (75%) and the IgM/IgG specificity ranged from 88.9% to 100% in the eight (100%) reviewed studies. The pooled data revealed that the average sensitivity and specificity was 70% and 94.5%, respectively. They agreed on its simplicity, fastness, and fewer requirements.
Conclusion: The GCIAs IgM/IgG rapid tests are simply fast and safe. Besides their short turnaround time, no specific equipment or skilled technicians’ requirements, they can serve as a rapid diagnostic test of RT–PCR-negative highly suspected patients and screening of SARS CoV-2 carriers. It cannot take the place of PCR, but the huge lab diagnosis pressure can be greatly relieved and more research is needed to detect its
reliability and clinical utility in limited-resource settings.
References
[2] Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24(3):91–8.
[3] World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. World Heal Organ. 2020;2019(3):1–7.
[4] Park S. Epidemiology, virology, and clinical features of severe acute respiratory syndrome - coronavirus- 2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020;63(4):119–24.
[5] World Health Organization. Coronavirus disease 2019 (COVID-19)Situation Report –99. WHO. 2020;14(6):1–12.
[6] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
[7] Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus–infected pneumonia. J Med Virol. 2020;92(6):680–2.
[8] Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. Am J Obstet Gynecol. 2020;222(5):1–12.
[9] Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6.
[10] Lovato A, de Filippis C. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. Ear Nose Throat J. 2020;99(4):1–3.
[11] Khedmat L. New Coronavirus (2019-nCoV): An Insight Toward Preventive Actions and Natural Medicine. Int Travel Med Cent Iran. 2020;8(1):44–5.
[12] World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO. 2020;2019(1):16–24.
[13] Denis M, Vandeweerd V, Verbeke R, Version: DV der V. Overview of information available to support the development of medical countermeasures and interventions against COVID-19. Transdiscipl Insights Living Pap. 2020;(4):1-173. DOI:10.5281/zenodo.3824324.
[14] Zhong BL, Luo W, Li HM, Zhang QQ, Liu XG, Li WT, et al. Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey. Int J Biol Sci. 2020;16(10):1745–52.
[15] Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, et al. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020;8(1):43.
[16] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Pharm Anal. 2020;10(2):102–8.
[17] Chen X, Yang Y, Huang M, Liu L, Zhang X, Xu J, et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center. J Med Virol. 2020;92(4):1–2.
[18] Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID- 19: The Disease and Tools for Detection. Am Chem Soc. 2020;14(4):3822–35.
[19] Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020;20(5):453–4.
[20] Kaul D. An overview of coronaviruses including the SARS-2 coronavirus – Molecular biology, epidemiology and clinical implications. Curr Med Res Pract. 2020;10(2):1–11.
[21] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. Am J Roentgenol. 2020;214(6):1280–6.
[22] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8.
[23] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
[24] Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19)and other viral outbreaks. Clin Chem Lab Med. 2020;58(7):1063–9.
[25] Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, et al. Long-term Co-existence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Non-severe Coronavirus Disease 2019 (COVID-19) Patients. medRxiv. 2020.
[26] Miodrag Stojanovic, Marija Apostolovic, Dijana Stojanovi, Zoran Miloševic, Aleksandra Toplaovi, Vesna Miti Lakušic MG. Understanding sensitivity, specificity and predictive values. Vojnosanit Pregl. 2014;71(12):1062–5.
[27] Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol. 2020;92(1):1–7.
[28] Hoffman T, Nissen K, Krambrich J, Rönnberg B, Akaberi D, Esmaeilzadeh M, et al. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol. 2020;10(1):4–6.
[29] Cassaniti I, Novazzi F, Giardina F, Salivaro F, Sachs M, Perlini S, et al. Performance of VivaDiagTMCOVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020;92(3):1–4.
[30] Dohla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health. 2020;182(5):170–2.
[31] Ying L, Yue-ping L, Bo D, Feifei R, Yue W, Jinya D, et al. Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2. MedRxiv. 2020;(3):1-13. DOI: 10.1101/2020.03.26.20044883.
[32] Xiang J, Yan M, Li H, Liu T, Lin C, Huang S, et al. Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). medRxiv. 2020;(4):1-13. DOI:10.1101/2020.02.27.20028787.
[33] Perez Garcia F, Perez-Tanoira R, Romanyk J, Arroyo T, Gomez-Herruz P, Cuadros-Gonzalez J. Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: a prospective single-center study. MedRxiv. 2020;(4):1-16. DOI:10.1101/2020.04.11.20062158.
[34] Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020;(4):1-15. DOI:10.1101/2020.04.09.20056325.
[35] Wang Wenling, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA - J Am Med Assoc. 2020;323(18):1843–4.
[36] Ren X, Liu Y, Chen H, Liu W, Guo Z, Zhang Y, et al. Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. Lancet. 2020;(2):1-22. DOI:10.2139/ssrn.3546086.
[37] Rodolfo C, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Brazilian J Infect Dis. 2019;24(2):180–7.
[38] Torres R, Rinder HM. Are SARS-CoV-2 Serologic Tests Safe Right Now? Richard. Am J Clin Pathol. 2020;153(6):709–11.
[39] Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv Prepr Serv Heal Sci. 2020;(3):1-18. DOI:10.1101/2020.03.18.20038059.
[40] Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since theexposure and post symptoms onset. medRxiv. 2020;(3):1-26. DOI: 10.1101/2020.03.23.20041707.
